Finasteride: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''finasteride''' (Proscar®) is "an orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of [[benign prostatic ...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''finasteride''' (Proscar®) is "an orally active [[testosterone 5-alpha-reductase]] inhibitor. It is used as a surgical alternative for treatment of [[benign prostatic hyperplasia]]."<ref>{{MeSH}}</ref> | In [[medicine]], '''finasteride''' (Proscar®) is "an orally active [[testosterone 5-alpha-reductase]] inhibitor. It is used as a surgical alternative for treatment of [[benign prostatic hyperplasia]]."<ref>{{MeSH}}</ref> | ||
Finasteride has also been found to reduce the incidence of [[prostate cancer]] in | ==History== | ||
Proscar brand of finasteride was approved by the [[Food and Drug Administration]] in the [[United States]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 1992.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=020180 Drugs@FDA]. U S Food and Drug Administration</ref> A generic version with a AB [[Food and Drug Administration/Catalogs/Therapeutic Equivalence Code|Therapeutic Equivalence Code]] was approved with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 200_.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&Search_Button=Submit&searchTerm=076436 Drugs@FDA]. U S Food and Drug Administration</ref> | |||
==Pharmacology== | |||
===Administration=== | |||
===Distribution=== | |||
===Metabolism=== | |||
===Excretion=== | |||
===Toxicity=== | |||
[[Drug toxicity]] includes | |||
==Uses== | |||
===Benign prostatic hypertrophy=== | |||
{{main|Benign prostatic hypertrophy}} | |||
===Prostate cancer prevention=== | |||
Finasteride has also been found to reduce the incidence of [[prostate cancer]] in a [[randomized controlled trial]]; however, the trial reported [[statistical significance]] in the increase in the risk of high grade prostate cancer.<ref name="pmid12824459">{{cite journal| author=Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al.| title=The influence of finasteride on the development of prostate cancer. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 3 | pages= 215-24 | pmid=12824459 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=12824459 | doi=10.1056/NEJMoa030660 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=14599370 Review in: J Fam Pract. 2003 Nov;52(11):833, 837] </ref> Subsequent analysis of the data suggests the incidence of high grade cancer is increased but without [[statistical significance]].<ref name="pmid19138953">{{cite journal| author=Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM| title=Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. | journal=Cancer Prev Res (Phila Pa) | year= 2008 | volume= 1 | issue= 3 | pages= 174-81 | pmid=19138953 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=12824459 | doi=10.1056/NEJMoa030660 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=14599370 Review in: J Fam Pract. 2003 Nov;52(11):833, 837] </ref> Subsequent analysis of the data suggests the incidence of high grade cancer is increased but without [[statistical significance]].<ref name="pmid19138953">{{cite journal| author=Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM| title=Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. | journal=Cancer Prev Res (Phila Pa) | year= 2008 | volume= 1 | issue= 3 | pages= 174-81 | pmid=19138953 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19138953 | doi=10.1158/1940-6207.CAPR-08-0092 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19138953 | doi=10.1158/1940-6207.CAPR-08-0092 }} </ref> | ||
Revision as of 17:28, 14 July 2010
In medicine, finasteride (Proscar®) is "an orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia."[1]
History
Proscar brand of finasteride was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 1992.[2] A generic version with a AB Therapeutic Equivalence Code was approved with a Abbreviated New Drug Application (ANDA) in 200_.[3]
Pharmacology
Administration
Distribution
Metabolism
Excretion
Toxicity
Drug toxicity includes
Uses
Benign prostatic hypertrophy
Prostate cancer prevention
Finasteride has also been found to reduce the incidence of prostate cancer in a randomized controlled trial; however, the trial reported statistical significance in the increase in the risk of high grade prostate cancer.[4] Subsequent analysis of the data suggests the incidence of high grade cancer is increased but without statistical significance.[5]
External links
The most up-to-date information about Finasteride and other drugs can be found at the following sites.
- Finasteride - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Finasteride - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Finasteride - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Finasteride (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. (2003). "The influence of finasteride on the development of prostate cancer.". N Engl J Med 349 (3): 215-24. DOI:10.1056/NEJMoa030660. PMID 12824459. Research Blogging. Review in: J Fam Pract. 2003 Nov;52(11):833, 837
- ↑ Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM (2008). "Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.". Cancer Prev Res (Phila Pa) 1 (3): 174-81. DOI:10.1158/1940-6207.CAPR-08-0092. PMID 19138953. Research Blogging.